The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Cholinergic nucleus basalis tauopathy emerges early in the aging‐MCI‐AD continuum
Abstract
The cholinergic denervation in Alzheimer's disease (AD) provides the rationale for treatments with anticholinesterases. The presence of this cholinergic lesion is solidly established in advanced AD. Whether it also exists in early disease remains unsettled. This question was addressed with thioflavin‐S histofluorescence to identify neurofibrillary tangles (NFT) and two tau antibodies (AT8, Alz‐50) to identify pre‐tangle cytopathology in the nucleus basalis, the source of cortical cholinergic innervation. Methods for the concurrent visualization of tauopathy and choline acetyltransferase were used to determine if the cytopathology was selectively located within cholinergic neurons. Five elderly index cases who had died at the stage of mild cognitive impairment (MCI) or early AD were identified by longitudinal neuropsychological and behavioral assessments. They were compared to 7 age‐matched cognitively normal subjects. NFT and AT8 (or Alz‐50) immunostaining in cholinergic nucleus basalis neurons existed even in the cognitively normal subjects. The percentage of tauopathy‐containing nucleus basalis neurons was greater in the cognitively impaired and showed a significant correlation with memory scores obtained 1‐18 months prior to death. These results show that cytopathology in cortical cholinergic pathways is a very early event in the course of the continuum that leads from advanced age to MCI and AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Moms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989) · Neurology · doi:10.1212/wnl.39.9.1159 · Cited by 4,130
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · cited 1×
“In 1976, two British teams reported that the presynaptic cholinergic marker choline acetyltransferase (ChAT) was depleted in the cerebral cortex of Alzheimer’s disease (AD).(1,2) These reports rapidly transformed AD from an obscure neuropathological entity, descriptively characterized by the presence of plaques and ta…”
BackgroundPopulation-Based Norms for the Mini-Mental State Examination by Age and Educational Level
Crum, R. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500180078038 · Cited by 2,929
A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary
Selnes, O. A. (1991) · Neurology · doi:10.1212/wnl.41.11.1856-a · Cited by 2,252
NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311
Augustinack, J. C., Schneider, A., Mandelkow, E.-M., & Hyman, B. T. (2002) · Acta Neuropathologica · doi:10.1007/s004010100423 · Cited by 998
Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease
Gamblin, T. C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A. L., Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1630428100 · Cited by 831
Cited by
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Self-citationClassification and basic pathology of Alzheimer disease
Duyckaerts, C., Delatour, B., & Potier, M.-C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0532-1 · Cited by 1,031
Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment
Scheff, S. W., Price, D. A., Schmitt, F. A., & Mufson, E. J. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.012 · Cited by 1,017
The Alzheimer's Disease Centers' Uniform Data Set (UDS): The Neuropsychologic Test Battery
Weintraub, S., Salmon, D., Mercaldo, N., Ferris, S., Graff-Radford, N. R., Chui, H., Cummings, J., DeCarli, C., Foster, N. L., Galasko, D., et al. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318191c7dd · Cited by 888
Self-citationSynaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment
Scheff, S. W., Price, D. A., Schmitt, F. A., DeKosky, S. T., & Mufson, E. J. (2007) · Neurology · doi:10.1212/01.wnl.0000260698.46517.8f · Cited by 824
Brain atrophy in Alzheimer’s Disease and aging
Pini, L., Pievani, M., Bocchetta, M., Altomare, D., Bosco, P., Cavedo, E., Galluzzi, S., Marizzoni, M., & Frisoni, G. B. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.002 · Cited by 836
The pathological process underlying Alzheimer’s disease in individuals under thirty
Braak, H., & Del Tredici, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0789-4 · Cited by 812
Peng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03135.x · Cited by 691
Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship
Nelson, P. T., Braak, H., & Markesbery, W. R. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181919a48 · Cited by 643
Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications
Mufson, E. J., Counts, S. E., Perez, S. E., & Ginsberg, S. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.11.1703 · Cited by 587
The road to restoring neural circuits for the treatment of Alzheimer's disease
Canter, R. G., Penney, J., & Tsai, L.-H. (2016) · Nature · doi:10.1038/nature20412 · Cited by 565
The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease
Braak, H., & Del Tredici, K. (2015) · Brain · doi:10.1093/brain/awv236 · Cited by 540
Mander, B. A., Winer, J. R., Jagust, W. J., & Walker, M. P. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.05.002 · Cited by 471
Neuropathologic Substrate of Mild Cognitive Impairment
Markesbery, W. R., Schmitt, F. A., Kryscio, R. J., Davis, D. G., Smith, C. D., & Wekstein, D. R. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.38 · Cited by 460
Grudzien, A., Shaw, P., Weintraub, S., Bigio, E., Mash, D. C., & Mesulam, M. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.007 · Cited by 396
Self-citationCholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease
Mesulam, M. ‐. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23415 · Cited by 375
Self-citationHampel, H., Mesulam, M.-M., Cuello, A. C., Khachaturian, A. S., Vergallo, A., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2018.43 · Cited by 369
Self-citationBasal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology
Schmitz, T. W., Nathan Spreng, R., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., Jagust, W., Trojanowki, J. Q., Toga, A. W., et al. (2016) · Nature Communications · doi:10.1038/ncomms13249 · Cited by 335
Self-citationAlzheimer's Disease and Mild Cognitive Impairment
Kelley, B. J., & Petersen, R. C. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.008 · Cited by 326
Concurrent Impairments in Sleep and Memory in Amnestic Mild Cognitive Impairment
Westerberg, C. E., Mander, B. A., Florczak, S. M., Weintraub, S., Mesulam, M.-M., Zee, P. C., & Paller, K. A. (2012) · Journal of the International Neuropsychological Society · doi:10.1017/s135561771200001x · Cited by 306
Self-citationChen, X.-Q., & Mobley, W. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00659 · Cited by 289
Rossini, P. M., Del Percio, C., Pasqualetti, P., Cassetta, E., Binetti, G., Dal Forno, G., Ferreri, F., Frisoni, G., Chiovenda, P., Miniussi, C., et al. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.08.049 · Cited by 281
Grothe, M., Heinsen, H., & Teipel, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.06.019 · Cited by 281
Cholinergic Dysfunction in Parkinson’s Disease
Müller, M. L. T. M., & Bohnen, N. I. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0377-9 · Cited by 264
The serotonergic system in ageing and Alzheimer's disease
Rodríguez, J. J., Noristani, H. N., & Verkhratsky, A. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.010 · Cited by 264
Bokde, A. L. W., Lopez-Bayo, P., Meindl, T., Pechler, S., Born, C., Faltraco, F., Teipel, S. J., Möller, H.-J., & Hampel, H. (2006) · Brain · doi:10.1093/brain/awl051 · Cited by 260
Mild cognitive impairment: pathology and mechanisms
Mufson, E. J., Binder, L., Counts, S. E., DeKosky, S. T., deToledo-Morrell, L., Ginsberg, S. D., Ikonomovic, M. D., Perez, S. E., & Scheff, S. W. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0884-1 · Cited by 257
Sleep architecture and the risk of incident dementia in the community
Pase, M. P., Himali, J. J., Grima, N. A., Beiser, A. S., Satizabal, C. L., Aparicio, H. J., Thomas, R. J., Gottlieb, D. J., Auerbach, S. H., & Seshadri, S. (2017) · Neurology · doi:10.1212/wnl.0000000000004373 · Cited by 241
Neuropathologic Alterations in Mild Cognitive Impairment: A Review
Markesbery, W. R. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1220 · Cited by 236
Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia.
Román, G. C., & Kalaria, R. N. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.10.004 · Cited by 213
Nanotechnology—novel therapeutics for CNS disorders
Srikanth, M., & Kessler, J. A. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.76 · Cited by 198
Reimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187
BABILONI, C., FRISONI, G., PIEVANI, M., VECCHIO, F., LIZIO, R., BUTTIGLIONE, M., GEROLDI, C., FRACASSI, C., EUSEBI, F., & FERRI, R. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.08.005 · Cited by 171
Constructing and Deconstructing Stem Cell Models of Neurological Disease
Han, S. S. W., Williams, L. A., & Eggan, K. C. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.003 · Cited by 159
Morawski, M., Brückner, G., Jäger, C., Seeger, G., & Arendt, T. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.05.022 · Cited by 156
Vana, L., Kanaan, N. M., Ugwu, I. C., Wuu, J., Mufson, E. J., & Binder, L. I. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.07.044 · Cited by 138
“These neurons develop NFTs consisting of various forms of tau early in the disease process.(15,17) In the present study, we provide evidence for the onset of intraneuronal TauC3 Neurons”
BackgroundInfluentialAnticholinergic drug use and risk for dementia: target for dementia prevention
Jessen, F., Kaduszkiewicz, H., Daerr, M., Bickel, H., Pentzek, M., Riedel-Heller, S., Wagner, M., Weyerer, S., Wiese, B., van den Bussche, H., et al. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-010-0156-4 · Cited by 119
Ginsberg, S. D., Che, S., Counts, S. E., & Mufson, E. J. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03641.x · Cited by 111
Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance
Geula, C., Dunlop, S. R., Ayala, I., Kawles, A. S., Flanagan, M. E., Gefen, T., & Mesulam, M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15471 · Cited by 102
Self-citationAmyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease
Vandenberghe, R., Adamczuk, K., Dupont, P., Laere, K. V., & Chételat, G. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.03.014 · Cited by 99
“These NFT stages correlate relatively well with neuronal loss and with the severity of clinical symptoms (Arriagada et al., 1992; Bancher et al., 1993; Giannakopoulos et al., 1998, 2003; Guillozet et al., 2003; Mesulam, 1999; Mesulam et al., 2004).”
BackgroundPseudo-phosphorylation of tau at Ser202 and Thr205 affects tau filament formation
Rankin, C. A., Sun, Q., & Gamblin, T. C. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2005.04.012 · Cited by 95
Babiloni, C., Pievani, M., Vecchio, F., Geroldi, C., Eusebi, F., Fracassi, C., Fletcher, E., De Carli, C., Boccardi, M., Rossini, P. M., et al. (2009) · Human Brain Mapping · doi:10.1002/hbm.20612 · Cited by 75
Pentz, R., Iulita, M. F., Ducatenzeiler, A., Bennett, D. A., & Cuello, A. C. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0797-2 · Cited by 68
Receptors for pro‐resolving mediators are increased in Alzheimer's disease brain
Emre, C., Hjorth, E., Bharani, K., Carroll, S., Granholm, A., & Schultzberg, M. (2020) · Brain Pathology · doi:10.1111/bpa.12812 · Cited by 60
Saif, N., Yan, P., Niotis, K., Scheyer, O., Rahman, A., Berkowitz, M., Krikorian, R., Hristov, H., Sadek, G., Bellara, S., et al. (2020) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.39 · Cited by 41
Han, D., Qureshi, H. Y., Lu, Y., & Paudel, H. K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m901095200 · Cited by 40
High levels of 27-hydroxycholesterol results in synaptic plasticity alterations in the hippocampus
Loera-Valencia, R., Vazquez-Juarez, E., Muñoz, A., Gerenu, G., Gómez-Galán, M., Lindskog, M., DeFelipe, J., Cedazo-Minguez, A., & Merino-Serrais, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-83008-3 · Cited by 37
Utility of quantitative EEG in early Lewy body disease
Massa, F., Meli, R., Grazzini, M., Famà, F., De Carli, F., Filippi, L., Arnaldi, D., Pardini, M., Morbelli, S., & Nobili, F. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.05.007 · Cited by 35
Scrascia, F., Curcio, G., Ursini, F., Trotta, L., Quintiliani, L., Migliore, S., Altamura, C., Pitocco, F., Altavilla, R., Melgari, J.-M., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130788 · Cited by 22
“The same was true for slowing EEG rhythms in AD subjects supposed to have an impairment of cholinergic basal forebrain [54, 57, 58].”
BackgroundSuzuki, Y., Suzuki, M., Shigenobu, K., Shinosaki, K., Aoki, Y., Kikuchi, H., Baba, T., Hashimoto, M., Araki, T., Johnsen, K., et al. (2022) · PLOS ONE · doi:10.1371/journal.pone.0265484 · Cited by 10
“Cholinergic losses in DLB affect both brainstem and basal forebrain presynaptic nuclei, in contrast to AD [34].”
Metadata
- Authors
- Mesulam, M., Shaw, P., Mash, D., & Weintraub, S.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2004-05-27
- Volume
- 55
- Issue
- 6
- Pages
- 815-828
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1980806973
- Cited by
- 374
- References
- 38
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.